Beam Therapeutics vs Gameto

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (38 vs 41)
Beam Therapeutics logo

Beam Therapeutics

GrowthBiotechnology

Base Editing Gene Therapy

Beam Therapeutics develops precision genetic medicines using base editing technology that makes single-letter DNA changes without cutting the double helix.

AI VisibilityBeta
Overall Score
D38
Category Rank
#1 of 1
AI Consensus
64%
Trend
up
Per Platform
ChatGPT
44
Perplexity
34
Gemini
29

About

Beam Therapeutics is a genetic medicines company founded in 2017 by base editing pioneers David Liu, J. Keith Joung, and Feng Zhang, having raised over $600M and gone public on Nasdaq. The company is built around base editing, a technology that makes precise single nucleotide changes in DNA without creating double-strand breaks, reducing the risk of unintended insertions or deletions compared to traditional CRISPR. Beam is developing a portfolio of base editing medicines targeting blood disorders, liver diseases, and immuno-oncology, including sickle cell disease, beta-thalassemia, and various cancers. The company also employs prime editing, a newer and even more precise gene editing modality for more complex genetic changes. Beam's pipeline includes both in vivo therapies delivered directly into the body and ex vivo cell therapy approaches where patient cells are edited outside the body and reinfused. As a clinical-stage company, Beam has programs in IND-enabling and Phase 1 trials and represents one of the most advanced next-generation gene editing platforms in development.

Full profile
Gameto logo

Gameto

EmergingBioTech

Reproductive Medicine

Gameto raised $70M Series B in 2024 for its stem cell technology that dramatically reduces IVF stimulation duration from 10 days to 2–3 days, making fertility treatment faster, cheaper, and less invasive.

AI VisibilityBeta
Overall Score
C41
Category Rank
#1 of 1
AI Consensus
53%
Trend
up
Per Platform
ChatGPT
49
Perplexity
39
Gemini
32

About

Gameto is revolutionizing in vitro fertilization by engineering ovarian granulosa cells from stem cells that can mature patient eggs in the lab, eliminating the lengthy and hormone-intensive stimulation protocols required by conventional IVF. The company's Fertilo technology co-incubates patient egg cells with Gameto's lab-grown granulosa cells, achieving maturation in 2–3 days versus the 10+ days of hormone injections that characterize standard IVF stimulation.

Full profile

AI Visibility Head-to-Head

38
Overall Score
41
#1
Category Rank
#1
64
AI Consensus
53
up
Trend
up
44
ChatGPT
49
34
Perplexity
39
29
Gemini
32
30
Claude
51
34
Grok
40

Key Details

Category
Base Editing Gene Therapy
Reproductive Medicine
Tier
Growth
Emerging
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Beam Therapeutics
Base Editing Gene Therapy
Only Gameto
Reproductive Medicine

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.